||This article or section is in the process of an expansion or major restructuring. You are welcome to assist in its construction by editing it as well. This template was placed by FeatherPluma (talk · contribs). If this article or section|
|Systematic (IUPAC) name|
|ATC code||A06AX04 (WHO)|
|Molar mass||1526.74 g/mol|
|(what is this?)|
Linaclotide (marketed under the trade name Linzess and Constella) is a peptide agonist of guanylate cyclase 2C. It was approved by the FDA in August 2012 for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C) in adults.
The National Institutes of Health (NIH) estimate that as many as 20% of Americans may experience irritable bowel syndrome, with approximately one-third of those affected experiencing constipation often accompanied by abdominal pain, affecting as many as 10 million Americans. Laxatives can assist with constipation but do not treat pain, while use of opiates to treat pain can aggravate constipation. While low-cost laxatives and pain killers would likely be tried first, linaclotide targets both associated conditions in a once-daily pill.
Linaclotide is a peptide agonist which mimics the action of endogenous guanylin and uroguanylin, both of which activate the cell surface receptor of guanylate cyclase 2C (GC-C).:108–109 The medication binds to the surface of the intestinal epithelial cells. Linaclotide is minimally absorbed and it is undetectable in the systemic circulation at therapeutic doses.:108 Activation of GC-C increases cyclic guanosine monophosphate (cGMP). Elevated cGMP stimulates secretion of chloride and bicarbonate and water into the intestinal lumen, mainly by way of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel activation. This results in increased intestinal fluid and accelerated transit. By elevating cGMP, linaclotide is also considered to reduce activation of colonic sensory neurons, reducing pain; and activates colonic motor neurons, which increases smooth muscle contraction and thus promotes bowel movements.
The approved dose for constipation-predominant irritable bowel syndrome (IBS-C) is 290 micrograms daily. The approved dose for chronic idiopathic constipation CIC is 145 mcg daily. The package insert has details of the medication's response rates and side effects.
The FDA approval of linaclotide was based on 4 large randomized trials, 2 for each indication: IBS-C and CIC. In a Phase III randomized double-blind clinical trial, 800 patients with IBS-C were given linaclotide or a placebo for 12 weeks. 34% of those receiving linaclotide experienced relief of pain and constipation, compared to 21% of patients who had taken the placebo. 50% of those receiving linaclotide saw a significant reduction in pain, versus 37% with the placebo, with pain reduction starting in the first week on the medication. 6% of patients left the study after experiencing diarrhea, the most commonly reported side effect.
Distribution and licensing
Under a partnership agreement announced in 2007 between Forest Laboratories and Microbia (as Ironwood Pharmaceuticals was then known), Forest would pay $70 million in licensing fees towards the development of linaclotide, with profits shared between the two companies. Distribution rights in the United States will be shared with Forest Laboratories, with Almirall distributing linaclotide in Europe and Astellas Pharma in Asia.
Linaclotide is a peptide consisting of 14 amino acids. The sequence is
- "FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation" Food and Drug Administration news release, August 30, 2012. Accessed April 28, 2016.
- Pollack, Andrew. "Drug for Irritable Bowel Achieves Goals in Trial", The New York Times, September 13, 2010. Accessed September 14, 2010.
- Hussain ZH, Everhart K, Lacy BE (2015). "Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies". Gastroenterol Hepatol (NY) 11 (2): 104–14. PMC 4836568. PMID 27099579.
- Linzess package insert, Allergan, Plc, revised November 2015. Accessed April 28, 2016.
- Yu SW, Rao SS (2014). "Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide". Therap Adv Gastroenterol 7 (5): 193–205. doi:10.1177/1756283X14537882. PMC 4107700. PMID 25177366.
- Staff. "Daily International Pharma Alert", FDANews, September 17, 2007, Vol. 4 No. 182. Accessed September 15, 2010.
- Albericio, F; Giraud, M; Gongora, M; Paradis, M; Tulla-Puche, J; Werbitzky, O. "Solid-Phase Synthesis of the Cys-rich Peptide Linaclotide" (PDF).
- Linzess information Drugs com Accessed October 23, 2013.